Edge Therapeutics, Inc. Business Finance Contracts & Agreements
26 Contracts & Agreements
- Exchange Agreements (2 contracts)
- Investor Rights Agreements (1)
- Loan Agreements (5)
- Registration Rights Agreements (1)
- Share Agreements (1)
- Stock Agreements (4)
- Subscription Agreements (1)
- Underwriting Agreements (4)
- Warrant Agreements (7)
- Share Transfer Agreement by and between PDS Biotechnology Corporation and Merck KGaA, Darmstadt, Germany (Filed With SEC on January 3, 2023)
- Venture Loan and Security Agreement, dated August 24, 2022, by and among Horizon Technology Finance Corporation, as a lender and collateral agent, Powerscourt Investments XXV, LP,... (Filed With SEC on November 14, 2022)
- Form of Warrant issued under the Venture Loan and Security Agreement, dated August 24, 2022 (Filed With SEC on November 14, 2022)
- Underwriting Agreement, dated June 15, 2021, by and among PDS Biotechnology Corporation and Cantor Fitzgerald & Co (Filed With SEC on June 17, 2021)
- Underwriting Agreement dated August 11, 2020 (Filed With SEC on August 13, 2020)
- Form of Underwriting Agreement (Filed With SEC on January 17, 2020)
- Common Stock Purchase Agreement, dated July 29, 2019 between PDS Biotechnology Corporation and Aspire Capital Fund, LLC (Filed With SEC on July 30, 2019)
- Registration Rights Agreement, dated July 29, 2019, between PDS Biotechnology Corporation and Aspire Capital Fund, LLC (Filed With SEC on July 30, 2019)
- Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Inducement Plan (Filed With SEC on June 20, 2019)
- Form of Subscription Agreement dated April 19, 2017, between Edge Therapeutics, Inc. and certain investors (Filed With SEC on April 19, 2017)
- Form of Employee Stock Option Agreement (Filed With SEC on March 2, 2017)
- Form of Executive Stock Option Agreement (Filed With SEC on March 2, 2017)
- Amended and Restated Loan and Security Agreement, dated as of August 1, 2016, by and between the Company and Hercules Capital, Inc (Filed With SEC on November 1, 2016)
- Warrant to Purchase 18,000 Shares of Common Stock issued to Maxim Partners LLC, dated as of October 6, 2015 (Filed With SEC on November 6, 2015)
- CONFIDENTIAL MATERIAL OMITTED AND FILEDSEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. AMENDMENT NO. 1 TO THE LICENSE AGREEMENT (Filed With SEC on September 21, 2015)
- EDGE THERAPEUTICS, INC. Common Stock, par value $0.00033 pershare UNDERWRITING AGREEMENT (Filed With SEC on September 21, 2015)
- AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (Filed With SEC on August 14, 2015)
- LOAN ANDSECURITY AGREEMENT (Filed With SEC on August 14, 2015)
- CONFIDENTIAL MATERIALOMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKSDENOTE SUCH OMISSIONS. LICENSE AGREEMENT (Filed With SEC on August 14, 2015)
- INVESTORSRIGHTS AGREEMENT byand among EdgeTherapeutics, Inc., VenrockHealthcare Capital Partners II, L.P., and theother Investors named herein April6, 2015 (Filed With SEC on August 14, 2015)
- EDGE THERAPEUTICS, INC. Preferred Stock Warrant (Filed With SEC on August 14, 2015)
- WARRANT AGREEMENT To Purchase Shares of Preferred Stock of EDGE THERAPEUTICS, INC. Dated as of August28, 2014 (the Effective Date) (Filed With SEC on August 14, 2015)
- EDGE THERAPEUTICS, INC. Preferred Stock Warrant (Filed With SEC on August 14, 2015)
- EDGE THERAPEUTICS, INC. WARRANT TO PURCHASE [______] SHARES OF COMMON STOCK (Filed With SEC on August 14, 2015)
- FIRST AMENDMENT TO WARRANT NO. 1 (Filed With SEC on August 14, 2015)
- EDGE THERAPEUTICS, INC. WARRANT TO PURCHASE 16,667 SHARES OF CAPITAL STOCK (Filed With SEC on August 14, 2015)
